ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0481

Subclinical Synovitis in Arthralgia: How Often Does It Result in Clinical Arthritis? A Longitudinal Study to Reflect on Starting Points for DMARD Treatment

Cleo Rogier1, Fenne Wouters2, Laurette van Boheemen3, Dirkjan van Schaardenburg4, Pascal de Jong1 and Annette van der Helm - van Mil5, 1Erasmus MC, Rotterdam, Netherlands, 2Leiden University Medical Center, Leiden, Netherlands, 3Amsterdam Rheumatology and immunology Center | Reade, Amste, Netherlands, 4Amsterdam Rheumatology and immunology Center | Reade and Amsterdam UMC, Amsterdam, Netherlands, 5Leiden University Medical Center, Erasmus Medical Center, Leiden, Netherlands

Meeting: ACR Convergence 2020

Keywords: Anti-citrullinated Protein Autoantibodies (ACPAs), Magnetic resonance imaging (MRI), rheumatoid arthritis, Synovitis, Ultrasound

  • Tweet
  • Email
  • Print
Session Information

Date: Friday, November 6, 2020

Title: RA – Diagnosis, Manifestations, & Outcomes I: Pre-Onset & Early RA (0479–0483)

Session Type: Abstract Session

Session Time: 3:00PM-3:50PM

Background/Purpose: According to guidelines, clinical arthritis is mandatory for diagnosing rheumatoid arthritis (RA). However, in the absence of clinical synovitis, imaging-detected subclinical synovitis is increasingly used instead, and considered as starting point for DMARD-therapy. We searched for evidence of the natural course and determined in arthralgia-patients with subclinical synovitis from three longitudinal cohorts the frequencies of non-progression to clinically apparent inflammatory arthritis (IA) (i.e ‘false-positives’).

Methods: Subclinical synovitis in hands or feet of arthralgia-patients was visualized with ultrasound (two cohorts, subclinical synovitis definition: greyscale≥2 and/or power doppler≥1) or MRI (one cohort, subclinical synovitis: synovitis score ≥1 by two readers). Patients were followed for 1-year on IA-development; two cohorts also had 3-year data. Analyses were stratified for anti-citrullinated protein antibody (ACPA).

Results: Subclinical synovitis at presentation was present in 36%, 41% and 31% in the three cohorts. Of the ACPA-positive arthralgia-patients with subclinical synovitis 54%, 44% and 68%, respectively, did not develop IA (Figure 1A). These percentages were even higher in the ACPA-negative arthralgia-patients: 66%, 85% and 89% (Figure 1A). Similar results were seen after 3-years follow-up (Figure 1B).

Conclusion: Replacing clinical arthritis by subclinical synovitis to identify RA introduces a high false positive rate (44-89%). DMARD-initiation in absence of clinical arthritis may lead to considerable overtreatment.

Figure 1 Percentage of arthralgia-patients with subclinical synovitis at baseline that did and did not develop inflammatory arthritis after 1-year (A) and 3-years follow-up (B), stratified for ACPA-status. Legend: (A) Percentage of patients with subclinical synovitis at baseline that did and did not progress to inflammatory arthritis after one year follow-up in three independent cohorts (ACPA-positive patients n=13, n=36, n=31, respectively; ACPA-negative patients n=47, n=157, n=19, respectively). (B) Percentage of patients with subclinical synovitis at baseline that did and did not progress to inflammatory arthritis after three year follow-up, in two independent cohorts (ACPA-positive patients n= 26, n=31, respectively; ACPA-negative patients n=121, n=19, respectively).


Disclosure: C. Rogier, None; F. Wouters, None; L. van Boheemen, None; D. van Schaardenburg, None; P. de Jong, None; A. van der Helm - van Mil, None.

To cite this abstract in AMA style:

Rogier C, Wouters F, van Boheemen L, van Schaardenburg D, de Jong P, van der Helm - van Mil A. Subclinical Synovitis in Arthralgia: How Often Does It Result in Clinical Arthritis? A Longitudinal Study to Reflect on Starting Points for DMARD Treatment [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/subclinical-synovitis-in-arthralgia-how-often-does-it-result-in-clinical-arthritis-a-longitudinal-study-to-reflect-on-starting-points-for-dmard-treatment/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/subclinical-synovitis-in-arthralgia-how-often-does-it-result-in-clinical-arthritis-a-longitudinal-study-to-reflect-on-starting-points-for-dmard-treatment/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology